| Line Item | 2025-12-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cost of Revenue | $30K | — | — |
| Gross Profit | -$1.2M | — | — |
| R&D Expense | $3.6M | — | -62.4% |
| SG&A Expense | $8.6M | — | -27.9% |
| Operating Income | -$13.5M | — | +37.6% |
| Net Income | -$23.1M | — | -232.7% |
| EPS (Basic) | -$0.38 | — | -152.8% |
| EPS (Diluted) | -$0.38 | — | -152.8% |
| Line Item | 2025-12-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $8.7M | +7.4% | +52.2% |
| Accounts Receivable | $115K | -92.3% | — |
| Inventory | $3.5M | +3.6% | +11.2% |
| Current Assets | $17.2M | -1.3% | +9.6% |
| Total Assets | $18.2M | -1.9% | +7.2% |
| Current Liabilities | $49.1M | +7.1% |
| Line Item | 2025-12-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$14.9M | — | -36.2% |
| Financing Cash Flow | $15.5M | — | +791.5% |
| +1.7% |
| Total Liabilities | $56.8M | +11.8% | -15.6% |
| Stockholders' Equity | -$38.5M | -19.8% | +23.3% |